The RECOVERY trial just released a preprint demonstrating benefit from tocilizumab in COVID-19. As with the prior RECOVERY studies, this is a multicenter, open-label, pragmatic trial. A robust mortality benefit was detected (the fragility index calculates to 17, which isn’t too shabby). Several important secondary endpoints were positive as well (e.g., reduced intubation rate, reduced […]
Most available data on atrial fibrillation pertains to chronic outpatient management or atrial fibrillation following cardiac surgery. This data may not apply perfectly to most critically ill patients. Extrapolation of available data to the management of critically ill patient is challenging, with much left to clinical judgement. The IBCC chapter is located 👉 here. The […]
The MENDS2 trial was intended as a study comparing dexmedetomidine to propofol. However, the doses of these medications used in the study weren’t high enough to be impactful. In retrospect, the study may actually be an investigation of how clinicians approach the agitated intubated patient – potentially revealing an over-reliance on opioid infusions.
Whether or not you have any interest in bamlanivimab, you should read this post as an amusing example of shoddy statistics being published in top journals. background & general landscape of the two trials The BLAZE-1 trial involved randomizing patients within three days of testing positive for COVID-19 to one of four arms: placebo, 700 […]